Showing results (371-380 of 389) with videos related to

Sort By:
Pageof 39
Cancer Science|September 14, 2020
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subsetMiyako Satouchi, Kaname Nosaki, Toshiaki Takahashi, et al.
Cancer Science|September 20, 2021
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subsetMiyako Satouchi, Kaname Nosaki, Toshiaki Takahashi, et al.
ESMO Open|July 22, 2020
Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR)Kyoichi Okishio, Ryo Morita, Junichi Shimizu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 16, 2019
Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in JapanRyo Morita, Kyoichi Okishio, Junichi Shimizu, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2025
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102)Yoshimasa Shiraishi, Takayuki Shimose, Motoko Tachihara, et al.
Cell Reports|August 2, 2023
Modulation of host glutamine anabolism enhances the sensitivity of small cell lung cancer to chemotherapyManabu Kodama, Gouji Toyokawa, Osamu Sugahara, et al.
The New England Journal of Medicine|November 21, 2017
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung CancerJean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, et al.
JAMA Oncology|December 21, 2023
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical TrialYoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, et al.
Oncotarget|May 10, 2014
Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group studyIsamu Okamoto, Kazuko Sakai, Satoshi Morita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2023
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURAJhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard, et al.
Pageof 39